Sorrento Therapeutics, Inc.·4

Sep 14, 5:00 PM ET

Janda Kim 4

4 · Sorrento Therapeutics, Inc. · Filed Sep 14, 2021

Insider Transaction Report

Form 4
Period: 2021-09-13
Janda Kim
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2021-09-13$3.50/sh+8,000$28,00011,000 total
  • Sale

    Common Stock

    2021-09-13$8.04/sh8,000$64,2853,000 total
  • Exercise/Conversion

    Non-qualified stock option

    2021-09-138,0000 total
    Exercise: $3.50Exp: 2021-09-28Common Stock (8,000 underlying)
Footnotes (3)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.84 to $8.23, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
  • [F3]25% of the shares subject to the option vested on September 28, 2012, and 1/48th of the shares subject to the option vested monthly thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION